



Edgar Filing: Cytosorbents Corp - Form 8-K

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

On March 31, 2014, CytoSorbents Corporation (the “Company”) conducted a conference call during which members of its senior management team discussed financial results for the fourth quarter and twelve months ended December 31, 2013, a business update, and certain other information. A copy of the transcript of the conference call and a powerpoint presentation is furnished herewith as Exhibits 99.1 and 99.2, respectively.

On March 31, 2014, the Company issued a press release announcing its financial results for the period ended December 31, 2013. A copy of the release is furnished herewith as Exhibit 99.3

**Item 9.01 Financial Statements and Exhibits.**

(d)Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Transcript of the Conference Call on March 31, 2014, 4:15pm EST (filed herewith).
99.2	Powerpoint presentation (filed herewith).
99.3	Press Release, dated March 31, 2014, relating to CytoSorbents Corporation's financial results for the period ended December 31, 2013 (filed herewith).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CYTOSORBENTS  
CORPORATION**

Date: April 4, 2014 By: /s/ Dr. Phillip P. Chan  
Dr. Phillip P. Chan

President and CEO